


DFW



WDN: gsh 09/30/05 4239-67017-01 434529 E-338-2003/0-US-01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of: Brechbiel et al.

Application No. 10/756,948

Filed: January 13, 2004

Confirmation No. 3278

For: METHODS FOR IMAGING THE  
LYMPHATIC SYSTEM USING  
DENDRIMER-BASED CONTRAST  
AGENTS

Examiner: Not yet assigned

Art Unit: 3736

Attorney Reference No. 4239-67017-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

*William D. Noonan*

Date Mailed

*Sept 30, 2005*

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Please return the enclosed postcard to confirm that the items listed above have been received.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By William D. Noonan  
William D. Noonan M.D.  
Registration No. 30,878

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing

	Attorney Docket Number	4239-67017-01
	Application Number	10/756,948
	Filing Date	January 13, 2004
	First Named Inventor	Brechbiel
	Art Unit	3736
	Examiner Name	Not yet assigned

### U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		6,426,059	July 30, 2002	Schmitt-Willich et al.
		5,101,827	April 7, 1992	Goldenberg

### FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		PCT	WO 2004/019998 A1	11 March 2004	The Government of the United States of America as Represented by the Secretary of Health and Human Services
		PCT	WO 03/001218 A2	3 January 2003	The Government of the United States of America as Represented by the Secretary of Health and Human Services

### OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		BRYANT, L. H. JR., et al., "Synthesis and Relaxometry of High-Generation (G = 5, 7, 9, and 10) PAMAM Dendrimer-DOTA-Gadolinium Chelates," <i>Journal of Magnetic Resonance Imaging</i> , Vol. 9, No. 2, pp 348-352, February 1999
		KOBAYASHI, HISATAKA, et al., "Avidin-Dendrimer-(1B4M-Gd) <sub>254</sub> : A Tumor-Targeting Therapeutic Agent for Gadolinium Neutron Capture Therapy of Intraperitoneal Disseminated Tumor Which can be Monitored by MRI," <i>Bioconjugate Chem</i> , Vol. 12, pp 587-593, 2001
		KOBAYASHI, HISATAKA, et al., "Dendrimer-Based Macromolecular MRI Contrast Agents: Characteristics and Application," <i>Molecular Imaging</i> , Vol. 2, No. 1, pp 1-10, January 2003

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	4239-67017-01
		Application Number	10/756,948
		Filing Date	January 13, 2004
		First Named Inventor	Brechbiel
		Art Unit	3736
		Examiner Name	Not yet assigned
		KOBAYASHI, HISATAKA, et al., "Dendrimer-Based Nanosized MRI Contrast Agents," <i>Current Pharmaceutical Biotechnology</i> , Vol. 5, pp 539-549, 2004	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	